RayKnowChina Research Map
Shortlist

RecruitingLymphomaN/A

Registered title, quoted from ClinicalTrials.gov

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking Union Medical College Hospital北京协和医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05514327, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed DLBCL(by central pathology review before enrolment)

    Inclusion criterion 2

  3. Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT

    Inclusion criterion 3

    Prior radiation therapy within 1 year of infusion

    Exclusion criterion 1

  4. Measurable disease at time of enrollment (the maximum diameter of cross section ≥1.5cm)

    Inclusion criterion 4

  5. Previous solid tumor within 3 years, previous or concurrent hematological malignancy

    Exclusion criterion 4

    HIV positive patients, active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive );

    Exclusion criterion 6

  6. Pregnant or nursing (lactating) women

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05514327, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Over than 18 years old
  • Histologically confirmed DLBCL(by central pathology review before enrolment)
  • Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
  • Measurable disease at time of enrollment (the maximum diameter of cross section ≥1.5cm)
  • Life expectancy ≥12 weeks
  • Able to receive radiotherapy evaluated by specialist

Exclusion Criteria:

  • Prior radiation therapy within 1 year of infusion
  • Pregnant or nursing (lactating) women
  • Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to infusion)
  • Previous solid tumor within 3 years, previous or concurrent hematological malignancy
  • Severe organ dysfunction: left ventricle ejection fraction (LVEF) <40%; DLCO <40%; estimated glomerular filtration rate (eGFR)<30mL/min/1.73 m2; total bilirubin >3 ULN
  • HIV positive patients, active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive );
  • Other conditions that the investigator may exclude due to risks or other possibilities

Quoted from ClinicalTrials.gov, NCT05514327, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05514327, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05514327